GlassScriptPhysician profile
Jaan A Kelly
NPI 1831189190
$5,964.06
in general payments reported to CMS, 2019-2025
40 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $1,261 · 2023: $1,102 · 2024: $1,263 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.50 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,555.15 | 2022-2025 | |
| Novo Nordisk INC | $853.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Revance Therapeutics, INC. | $394.33 | 2024-2025 | Daxxify |
| Axsome Therapeutics, INC. | $274.66 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Amgen INC. | $246.08 | 2022-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $231.11 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $190.65 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $187.02 | 2021-2024 | |
| Esperion Therapeutics, INC. | $179.83 | 2022-2025 | Nexletol |
| Glaxosmithkline, LLC. | $176.16 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $168.91 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.70 | 2022-2025 | Caplyta |
| Lundbeck LLC | $133.97 | 2022-2025 | Rexulti |
| Genentech USA, INC. | $116.57 | 2021 | |
| Alnylam Pharmaceuticals INC. | $114.86 | 2025 | Onpattro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaan Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.